Prognostic significance of annexin A2 and annexin A4 expression in patients with cervical cancer

BMC Cancer

Table 1 Correlation between annexin expression and the clinicopathological characteristics of patients with cervical cancer

Group	No	ANXA2		ANXA4
Group	No	Mean histoscore [95 % CI]	P value	Mean histoscore (95 % CI)	P value
Normal	46	133 [111–156]	0.002	34 [21–46]	<0.001
Cancer	336	94 [88–101]		73 [65–81]
Age
<50 year	203	95 [87–103]	0.731	79 [68–89]	0.096
>50 year	133	93 [83–103]		65 [53–77]
FIGO Stage
≤ IIA	291	90 [83–97]	0.002	74 [66–83]	0.543
≥ IIB	45	121 [103–138]		67 [47–88]
Cell type
SCC	256	101 [93–108]	<0.001	51 [44–58]	<0.001
AD/ASC	80	73 [62–84]		145 [126–163]
Tumor size
≤4 cm	256	90 [82–97]	0.010	76 [66–85]	0.317
>4 cm	80	109 [96–121]		66 [49–83]
LVSI
Negative	202	88 [80–96]	0.019	83 [72–93]	0.005
Positive	133	104 [93–114]		60 [48–72]
Depth of invasion
<50 %	108	70 [60–80]	<0.001	70 [55–84]	0.565
≥50 %	228	106 [98–113]		75 [65–85]
LN metastasis
Negative	256	88 [81–95]	0.002	76 [66–85]	0.250
Positive	80	113 [100–127]		65 [50–81]
PM involvement
Negative	305	92 [85–98]	0.031	74 [65–82]	0.662
Positive	31	118 [95–141]		68 [42–94]
Resection margin
Negative	323	94 [87–100]	0.420	75 [66–83]	0.032
Positive	13	111 [66–157]		43 [15–71]
Primary Treatment
OP only	171	82 [73–90]	<0.001	78 [66–90]	0.354
OP + RT	70	110 [95–125]		71 [53–89]
OP + CCRT	90	107 [95–119]		68 [54–82]
Neoadjuvant	5	75 [45–105]		26 [8–59]

ANX annexin, FIGO International Federation of Gynecology and Obstetrics, SCC squamous cell carcinoma, AD adenocarcinoma, ASC adenosquamous cell carcinoma, LVSI lymphovascular space invasion, LN lymph node, PM parametrium, OP operation, RT radiotherapy, CCRT concurrent chemoradiation